Xellia Pharmaceuticals, Europe’s last manufacturer of key antibiotic ingredients, is closing its Copenhagen factory and moving production to China, impacting the EU’s goal of reducing reliance on Asian suppliers. The closure will result in 500 job losses, with the company urging EU governments to support generic medicine pricing to retain production within Europe. Xellia’s CEO warned that without intervention, nearly all active pharmaceutical ingredients could soon originate from China, undermining EU control over critical medicines.
